Simulations Plus delivered a strong second quarter with 8% revenue growth to $24.3 million, supported by robust software and service segment performance, and maintained solid margins and client renewal rates.

• Total revenue rose 8%, driven by 9% software and 8% service segment growth, surpassing guidance.
• Software revenue from ADMET Predictor grew 19%, reflecting ongoing strength in discovery applications.
• Client base expanded to 297 with an average revenue per client of $124,000 and a renewal rate of 91% for the quarter.
• The company is strategically leveraging AI, establishing collaborations with major pharmaceutical firms to embed AI into drug development workflows.
• Despite near-term challenges in clinical operations revenue, the firm’s long-term positioning remains focused on durable scientific engines and AI-enhanced biosimulation solutions.